Pearce IP BioBlast®: w/e 13 May 2022

by , | May 17, 2022

04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue.  Amneal announced that it plans to expand into high growth areas including biosimilars and injectables.

10 May 22 | Formycon and Athos KG announced closing of the acquisition by Formycon of 100% of the rights to FYB201 (biosimilar ranibizumab), a 50% of the rights to FYB202 (biosimilar ustekinumab), together with Bioeq GMBH, which is described as its “long-time partner”.  The total value of the deal is €650M.

10 May 22 | Merck announced that it will present data from studies of six medicines and pipeline candidates in more than 25 cancers at the 2022 American Society of Clinical Oncology Annual Meeting in June.  This will include data on Keytruda® (ustekinumab), Lenvima® (lenvatinib) and its investigational anti-LAG-3 therapy favezelimab.

10 May 22 | JSR Life Sciences announced the launch of a new business division, Similis Bio.  Similis Bio plans to operate a partnering program to help biopharmaceutical companies improve the efficiency and cost of biosimilar development programs.

11 May 22 | Alvotech announced that it will hold an Extraordinary General Meeting of shareholders to approve the pending business combination with Oaktree Acquisition Corp. II. (Oaktree) on 07 June 2022.  Alvotech has filed the proxy statement/prospectus with the US SEC and the SEC has declared the Registration Statement on Form F-4 effective.  On 7 December 2021, Alvotech and Oaktree announced that they had entered into a merger agreement for the creation of a publicly-traded global biopharmaceutical company.

Pearce IP offers Australian based, generics and biosimilars focused lawyers, attorneys and regulatory affairs experts, with incomparable global experience, technical competence, and commercial elegance.  Call us today on 02 9023 9988 or email

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News